Kallyope has raised $236m in a Series D funding round led jointly by Mubadala Investment Company and The Column Group for advancing gut-brain axis treatment programmes.
Various new investors including DNS Capital, Hartford Healthcare Endowment, Parkwood and Tao Capital took part in the financing round.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Previous investors Alexandria Venture Investments, Bill Gates and Casdin Capital, among others, participated in the funding round.
The Series D funding proceeds will be utilised to develop Kallyope’s drug discovery platform, clinical trials and pipeline comprising several programmes across a wide range of treatment areas.
Kallyope has created a platform that incorporates various technologies to discover and translate gut-brain biology.
By unveiling the links between the gut and the brain, the platform was used to create new programmes in various significant treatment areas, including immunology and inflammation, metabolism and ailments of the central nervous system.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFour compounds in two lead programmes of Kallyope in Type 2 diabetes, obesity and ailments of gastrointestinal barrier progressed into clinical trials over the past 13 months.
With the latest funds, the company will advance these trials and expedite progress on over 20 programmes and molecules that are currently in its pipeline.
The proceeds will also be used to make an investment in the platform to boost leadership in this area.
So far, the company raised approximately $480m, including a $112m through Series C funding round in March 2020.
Kallyope president and CEO Jay Galeota said: “Since our inception six years ago, Kallyope has pioneered research on the gut-brain axis and developed a transformational drug discovery platform with speed and ingenuity.
“We are pleased with the support of an outstanding group of investors who represent a strong vote of confidence in our science and our team.”
